Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
In the PROSPER Phase III study (n=1,401), the addition of enzalutamide to androgen-deprivation therapy (ADT) was associated with prolonged median overall survival (67.0 months v 56.3 months placebo plus ADT; HR 0.73; 95% CI 0.61-0.89; p=0.001).
Source:
New England Journal of Medicine
SPS commentary:
A related editorial discusses the results of this study and the HERO Phase III study of the oral gonadotropin-releasing hormone antagonist relugolix in men with advanced prostate cancer, also published early online. The authors say that when considered together, these trials raise the question of whether the use of a GnRH antagonist, either oral or subcutaneous, might result in improved cardiovascular outcomes, especially for those at highest risk.